A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

被引：4
|
作者：
DiNardo, Courtney D. [1 ]
Olin, Rebecca [2 ]
Ishizawa, Jo [1 ]
Sumi, Hiroyuki [3 ]
Xie, Jingdong [4 ]
Kato, Kazunobu [4 ]
Kumar, Prasanna [4 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif San Francisco, Hellen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Daiichi Sankyo Co Ltd, Tokyo, Japan
[4] Daiichi Sankyo Inc, Basking Ridge, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3932
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Borthakur, Gautam
    Konopleva, Marina
    Ravandi, Farhad
    Wierda, William G.
    Estrov, Zeev
    Faderl, Stefan
    Kadia, Tapan
    Rey, Kristy
    Cheung, Cora
    Kantajian, Hagop M.
    [J]. BLOOD, 2011, 118 (21) : 1122 - 1122
  • [2] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    [J]. BLOOD, 2014, 124 (21)
  • [3] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Attar, Eyal C.
    Amrein, Philip C.
    Fraser, James W.
    Fathi, Amir T.
    McAfee, Steven
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Stone, Richard M.
    Foster, Julia
    Neuberg, Donna
    Ballen, Karen K.
    [J]. LEUKEMIA RESEARCH, 2013, 37 (09) : 1016 - 1020
  • [4] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Amrein, Philip C.
    Attar, Eyal C.
    Fathi, Amir Tahmasb
    McAfee, Steven L.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Foster, Julia
    Stone, Richard M.
    Neuberg, Donna S.
    Ballen, Karen K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.
    Daver, Naval Guastad
    Stevens, Don A.
    Hou, Jing-Zhou
    Yamauchi, Takahiro
    Moshe, Yakir
    Fong, Chun Yew
    Marzocchetti, Angela
    Adamec, Ryan
    Patel, Maulik
    Lambert, Stacie
    Wu, Kevin
    Rollig, Christoph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
    Groevdal, M.
    Kahn, R.
    Jansson, M.
    Aggerholm, A.
    Antunovic, P.
    Astermark, J.
    Bernell, P.
    Engstroem, L.
    Kjeldsen, L.
    Linder, O.
    Nilsson, L.
    Olsson, A.
    Skovholm, M.
    Tangen, J.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S49 - S50
  • [7] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
    Freyrie, A.
    Reda, G.
    Vincenti, D.
    Ferla, V.
    Orofino, N.
    Sciume, M.
    Guidotti, F.
    Cortelezzi, A.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
  • [8] Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy
    Grovdal, Michael
    Khan, Rasheed
    Aggerholm, Anni
    Antunovic, Petar
    Astermark, Jan
    Bernell, Per
    Engstroem, Lena-Maria
    Kjeldsen, Lars
    Linder, Olle
    Nilsson, Lars
    Olsson, Anna
    Wallvik, Jonas
    Tangen, Jon Magnus
    Oeberg, Gunnar
    Jacobsen, Sten Eirik
    Porwit, Anna
    Hokland, Peter
    Helistrom-Lindberg, Eva
    [J]. BLOOD, 2008, 112 (11) : 89 - 89
  • [9] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    [J]. BLOOD, 2013, 122 (21)
  • [10] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
12345